Choose your location

Latest
'Loaded with potential': stage version of TV smash It's a Sin has the dancefloor at its heart ‘Pull back the curtain’ on treatment of sexual assault victims in court, says UK government adviser Tanzid Tamim rues 'unlucky' last-ball dismissal for Towhid Hridoy USC vs. Indiana score, live updates: Latest from Trojans-Hoosiers in Big Ten showdown Wales’ Dewi Lake calls historic win against New Zealand ‘amazing feeling’ CDC Travel Health Notices: Key Outbreak Alerts for Clinicians

Omalizumab Linked to 0 Epinephrine Use in Alpha-Gal Syndrome

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026. Among 64 patients with alpha-gal syndrome (AGS) treated...

HCPLive Chelsie Derman

No patients with alpha-gal syndrome needed epinephrine for a food reaction during omalizumab therapy in a 64-patient cohort presented at ACAAI 2026. Among 64 patients with alpha-gal syndrome (AGS) treated with omalizumab (Xolair), none required epinephrine for a food-triggered reaction during therapy, according to a retrospective cohort analysis presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona.1 Despite strict avoidance of mammalian-derived foods and products, patients with AGS remain vulnerable to accidental exposures and recurrent anaphylaxis requiring epinephrine.1 Real-world evidence on how omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, affects severe allergic outcomes in this population has been limited.1 “These findings suggest that omalizumab may offer an additional layer of protection for patients living with alpha-gal syndrome,” said Collette Tilly, MD, lead author of the study and allergy & immunology fellow-in-training at the University of North Carolina at Chapel Hill, in a statement.

Omalizumab Efficacy in Alpha-Gal Syndrome: Epinephrine Use and Anaphylaxis Burden Tilly and colleagues conducted a retrospective cohort analysis of 64 patients with confirmed AGS treated with omalizumab between April 2022 and November 2025.1 Inclusion required a compatible clinical history, positive alpha-gal-specific IgE, and at least 3 months of follow-up.

The primary endpoint was food-related epinephrine utilization during therapy.1 The median patient age was 55 years (range, 20-89 years), and 56% of patients were female.1 The cohort carried substantial baseline risk: 81% had documented anaphylaxis, and 53% had required epinephrine before starting omalizumab.1 Across a median treatment duration of 23 months (range, 3-83 months), no patients required epinephrine for a food-triggered reaction.1 The investigators described the finding as complete elimination of food-related epinephrine utilization in a high-risk cohort with substantial baseline anaphylaxis.1 Mammalian Product Reintroduction and Omalizumab Safety in AGS Nearly all patients reported benefit on the secondary outcome of reaction burden.

A patient-defined, clinically meaningful reduction in reaction frequency or severity was reported by 95% of the cohort.1 Reintroduction of mammalian foods and/or products was achieved in 31% of patients. This included full reintroduction in 13% and partial reintroduction in 19%.1 Adverse events were infrequent and predominantly mild, with arthralgias reported most commonly.

Only 3% of patients discontinued omalizumab because of adverse events, and the investigators characterized the agent’s tolerability as favorable.1 Omalizumab is produced in Chinese hamster ovary cells, which may variably express alpha-gal. 3 Prior HCPLive coverage noted this creates a theoretical anaphylaxis risk warranting appropriate precautions at initiation in patients with AGS.

References Tilly C, Commins S. Omalizumab eliminates epinephrine use and reduces anaphylaxis burden in alpha-gal syndrome. Abstract A025.

Presented at: American College of Allergy, Asthma and Immunology 2026 Annual Scientific Meeting; November 12-16, 2026; Phoenix, AZ. Patients with meat allergy who take omalizumab may see improvement of symptoms. American College of Allergy, Asthma and Immunology.

Published November 12, 2026. Accessed November 13, 2026. https://annualmeeting.acaai.org/patients-meat-allergy.cfm?utm_source=Registrants&utm_campaign=3937e8f549-EMAIL_CAMPAIGN_2020_11_03_09_12_COPY_01&utm_medium=email&utm_term=0_bfcb93257f-3937e8f549-142668538 Alpha-gal syndrome: closing an underrecognized allergy diagnostic gap.

HCPLive. https://www.hcplive.com/view/alpha-gal-syndrome-closing-underrecognized-allergy-diagnostic-gap . Published September 4, 2026. Accessed November 13, 2026.

Related to this article

Article text via FreeNewsAPI. Rights remain with HCPLive.

Read on publisher site → Opens HCPLive in a new tab

More in Local